ストックスクリーナーアプリを入手
0.6845
1.29%
0.0087
アフターアワーズ：
.69
0.0055
+0.80%
Metavia Inc (MTVA) 最新ニュース
MetaVia Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
MetaVia Completes $10 Million Private Placement - TipRanks
MetaVia launches $10M private placement - MSN
MetaVia secures $10 million in private placement - Investing.com
MetaVia (MTVA) to Raise $10M Through Private Placement | MTVA St - GuruFocus
MetaVia secures $10 million in private placement By Investing.com - Investing.com South Africa
MetaVia announces $10M private placement - TipRanks
MetaVia Inc. announced that it expects to receive $9.995395 million in funding - marketscreener.com
Metavia Announces $10 Million Private Placement Priced At-The-Market Under Nasdaq Rules - marketscreener.com
MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules - Eastern Progress
MetaVia Unveils Promising DA-1241 Trial Results - TipRanks
Asian shares get a lift from plans for China-US trade talks, Beijing stimulus moves - WFMZ.com
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 - PR Newswire
Metavia Presents Data On DA-1241, A GPR119 Agonist, Demonstrating Both Hepatoprotective And Glucose-Regulating Effects In Patients With Presumed MASH, At The EASL Congress 2025 - MENAFN.com
Senate confirms Bisignano to lead Social Security Administration as agency faces DOGE overhaul - WFMZ.com
Trump’s meme coin business racks up fees as buyers jump at the chance for access to the president - WFMZ.com
MetaVia Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
MetaVia’s Promising Clinical Trial Results and Future Prospects Drive Buy Rating - TipRanks
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial By Investing.com - Investing.com South Africa
Copper Miner Rallies as Takeover Buzz Sparks Investor Optimism - The Globe and Mail
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 - Eastern Progress
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial - Investing.com
MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors - insights.citeline.com
MetaVia reports promising obesity drug trial results By Investing.com - Investing.com South Africa
How will MetaVia Inc’s (MTVA) earnings compare to estimates this quarter? - uspostnews.com
RIVN’s Q2 earnings predictions: What the experts say - uspostnews.com
Can Newell Brands Inc (NWL) meet market expectations this quarter? - uspostnews.com
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential - The Malaysian Reserve
MetaVia (MTVA) Advances DA-1726 in Obesity Treatment with Promis - GuruFocus
MetaVia Reports Positive Phase 1 Trial Results - TipRanks
MetaVia (MTVA) Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726 - StreetInsider
MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential - marketscreener.com
MetaVia's New GLP-1 Drug Achieves 6.3% Weight Loss in Just 26 Days: Phase 1 Trial Reveals Promising Safety Profile - Stock Titan
Stock Market Recap: MetaVia Inc (MTVA) Concludes at 0.74, a 0.64 Surge/Decline - DWinneX
MetaVia’s (MTVA) Buy Rating Reiterated at HC Wainwright - Defense World
Health Beat: Medical milestone: First drug for sleep apnea - WFMZ.com
MTVA stock touches 52-week low at $0.7 amid sharp annual decline - Investing.com Canada
MTVA stock touches 52-week low at $0.7 amid sharp annual decline By Investing.com - Investing.com South Africa
MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%… - Zacks Small Cap Research
Korean Dental Association forms election planning team to enhance public oral healthCHOSUNBIZ - Chosunbiz
MetaVia’s obesity drug cuts body weight by 6.3% in 26 days in phase 1 - koreabiomed.com
MetaVia reports positive obesity drug trial results By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.39% - Investing.com
United States shares lower at close of trade; Dow Jones Industrial Average down 0.39% - Investing.com India
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
MetaVia Reports 'Positive' Results for Obesity Treatment in Part 2 of Phase 1 Trial - marketscreener.com
Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Smart Shirt Might Predict Heart Problems - WFMZ.com
MetaVia reports positive obesity drug trial results - Investing.com Australia
MetaVia Announces Positive Phase 1 Trial Results - TipRanks
Metavia Announces Positive Top-Line Data From The 4-Week Phase 1 Mad Trial Of Da-1726 - marketscreener.com
MetaVia announces ‘positive’ results from Part 2 of Phase 1 trial of DA-1726 - TipRanks
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):